As most patients with HCC suffer from underlying cirrhosis [4], bleeding and venous thromboembolism are of major interest in HCC patients treated with anti-VEGF(R) treatments, as VTE is not only a complication of malignancy but may also develop as a consequence to treatment with different VEGF(R) inhibitors [30]. The gene discussed is VEGFA; the disease is Cirrhosis.